Mehra Golshan
Yale University
196 Papers
737 Citations
Mehra Golshan is an academic researcher from Yale University. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 39, co-authored 186 publications. Previous affiliations of Mehra Golshan include Northwestern University & University of Illinois at Chicago.
Chat about Author
Papers
Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Results from BrighTNess phase III study.
Otto Metzger Filho,Daniel G. Stover,Sarah Asad,Peter Ansell,Mark A. Watson,Sibylle Loibl,Charles E. Geyer,Joyce O'Shaughnessy,Michael Untch,Hope S. Rugo,Jens Huober,Mehra Golshan,William M. Sikov,Gunter von Minckwitz,Priya Rastogi,David Maag,Norman Wolmark,Carsten Denkert,William Fraser Symmans +18 more
TL;DR: Achievement of pathologic complete response with neoadjuvant chemotherapy with NAC remains unknown in TNBC and the interplay between immunophenotype, tumor proliferation (prolif) and achievement of pathological complete response (pCR) with Nac remains unknown.
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase 3 trial.
CE Geyer,William M. Sikov,Jens Huober,Hope S. Rugo,Norman Wolmark,Joyce O'Shaughnessy,David Maag,Michael Untch,Mehra Golshan,Jose Juan Ponce Lorenzo,Otto Metzger,Martin Dunbar,W. Fraser Symmans,PS Rastogi,J. Sohn,Robyn R. Young,Gail S. Wright,C. Harkness,Kristi McIntyre,Denise A. Yardley,Sibylle Loibl +20 more
TL;DR: The BrighTNess trial as discussed by the authors showed that the addition of carboplatin with/without veliparib to neoadjuvant chemotherapy significantly improved pathological complete response (pCR) rates with manageable acute toxicity in patients with triple-negative breast cancer (TNBC).
Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer: Translational Breast Cancer Research Consortium trial 017
Jennifer F. De Los Santos,Alan B. Cantor,Keith D. Amos,Andres Forero,Mehra Golshan,Janet K. Horton,Clifford A. Hudis,Nola M. Hylton,Kandace P. McGuire,Funda Meric-Bernstam,Ingrid M. Meszoely,Rita Nanda,E. Shelley Hwang +12 more
TL;DR: The objective of this multicenter, retrospective study was to estimate the accuracy of preoperative magnetic resonance imaging (MRI) in predicting a pCR in the breast.
Interim clinical trial analysis of intraoperative mass spectrometry for breast cancer surgery
Sankha S. Basu,Sylwia A. Stopka,Walid M. Abdelmoula,Elizabeth C. Randall,Begoña Gimenez-Cassina Lopez,Michael S. Regan,David Calligaris,Fa-Ke F. Lu,Isaiah Norton,Melissa Anne Mallory,Sandro Santagata,Deborah A. Dillon,Mehra Golshan,Mehra Golshan,Nathalie Y. R. Agar,Nathalie Y. R. Agar +15 more
- 09 Sep 2021
TL;DR: In this article, a liquid micro-junction surface sample probe (LMJ-SSP) was used to assess breast cancer margins in an intra-operative clinical application of Mass Spectrometry (MS) within the operating room.
Surgery of the primary tumor in de novo metastatic breast cancer: To do or not to do?
Carmen Criscitiello,Mario Giuliano,Giuseppe Curigliano,M. De Laurentiis,Grazia Arpino,Nicola Carlomagno,S. De Placido,Mehra Golshan,Michele Santangelo +8 more
TL;DR: A critical overview of the literature focusing on the rationale and potential role of primary tumour excision in patients with de novo metastatic breast cancer is presented.